A phase I study of HMPL-523, a selective oral anti-spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma

Annals of Oncology - Tập 30 - Trang v447 - 2019
N. Fowler1, W. Jurczak2, R. Cordoba Mascunano3, P. Abrisqueta Costa4, P. Strati5, C. Yang6, M. Kania7, J. Kauh7, A.J.M. Ferreri8
1Division of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX, USA
2Department of Haematology, Jagiellonian University Collegium Medicum, Krakow, Poland
3Department of Hematology, University Hospital Fundacion Jimenez Diaz, Madrid, Spain
4Department of Hematology-Oncology, Hospital Vall d’Hebron de Barcelona, Barcelona, Spain
5Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA
6Clinical Research, Hutchison Medipharma Ltd, Shanghai, China
7Clinical Development, Hutchison Medipharma (US) Inc, Florham Park, NJ, USA
8Department of Oncology-Hematology, IRCCS Ospedale San Raffaele, Milan, Italy

Thông tin
Thông tin xuất bản

Annals of Oncology

Tập 30

v447

Thông tin tác giả